NK/T-CELL LYMPHOMA
Clinical trials for NK/T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new NK/T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for NK/T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to stop lymphoma from coming back after transplant
Disease control Not yet recruitingThis study is testing a new three-drug combination given to patients before a stem cell transplant. The goal is to see if this new preparation method is more effective and safer for people with NK/T-Cell Lymphoma, specifically aiming to keep the cancer from returning after the tr…
Matched conditions: NK/T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Three-Pronged attack on deadly lymphoma shows promise
Disease control Not yet recruitingThis study is testing whether combining three different drugs works better than current treatments for an aggressive type of blood cancer called NK/T-cell lymphoma. The trial will involve 40 adults with advanced disease who haven't had prior treatment. Researchers hope this combi…
Matched conditions: NK/T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: LIANG WANG • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New combo therapy aims to stop Lymphoma's return after transplant
Disease control Not yet recruitingThis study is testing a two-drug maintenance therapy for people with NK/T-cell lymphoma who have already received a stem cell transplant. The goal is to see if taking the drugs selinexor and azacitidine after the transplant can help keep the cancer from coming back. Researchers w…
Matched conditions: NK/T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Mar 10, 2026 12:52 UTC